Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.

被引：0
|
作者：
Fukuda, Koshiro
Ooki, Akira
Osumi, Hiroki
Fukuoka, Shota
Yoshino, Koichiro
Tamba, Mikako
Udagawa, Shohei
Shimozaki, Keitaro
Ogura, Mariko
Wakatsuki, Takeru
Chin, Keisho
Fujishiro, Mitsuhiro
Shinozaki, Eiji
Yamaguchi, Kensei
机构：
[1] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Koto, Japan
[3] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [21] The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer
    Sawaki, A.
    Ohashi, Y.
    Omuro, Y.
    Satoh, T.
    Hamamoto, Y.
    Boku, N.
    Miyata, Y.
    Takiuchi, H.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [22] Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
    Jun Wang
    Na Sun
    Thomas Kunzke
    Jian Shen
    Annette Feuchtinger
    Qian Wang
    Raphael Meixner
    Ronan Le Gleut
    Ivonne Haffner
    Birgit Luber
    Florian Lordick
    Axel Walch
    British Journal of Cancer, 2024, 130 : 1036 - 1045
  • [23] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Chen, Shang-Chiung
    Kagedal, Matts
    Gao, Yuying
    Wang, Bei
    Harle-Yge, Marie-Laurence
    Girish, Sandhya
    Jin, Jin
    Li, Chunze
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1147 - 1159
  • [24] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1147 - 1159
  • [25] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [26] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
  • [27] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [28] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [29] Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
    Gomez-Martin, Carlos
    Carlos Plaza, Jose
    Pazo-Cid, Roberto
    Salud, Amonieta
    Pons, Francesc
    Fonseca, Paula
    Leon, Ana
    Alsina, Maria
    Visa, Laura
    Rivera, Fernando
    Carmen Galan, M.
    del Valle, Elena
    Vilardell, Felipe
    Iglesias, Mar
    Fernandez, Soledad
    Landolfi, Stefania
    Cuatrecasas, Miriam
    Mayorga, Marta
    Jose Ponles, M.
    Sanz-Moncasi, Pilar
    Montagut, Clara
    Garralda, Elena
    Rojo, Federico
    Hidalgo, Manuel
    Lopez-Rios, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : 4445 - +
  • [30] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 365 - 365
12345